These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
11. Eculizumab for Shiga-toxin-induced hemolytic uremic syndrome in adults with neurological involvement. Lee BJ; Arter Z; Doh J; Griffin SP; Vittayawacharin P; Atallah S; Shieh KR; Tran MH; Jodele S; Kongtim P; Ciurea SO EJHaem; 2024 Jun; 5(3):548-553. PubMed ID: 38895057 [TBL] [Abstract][Full Text] [Related]
12. HUS with mutations in CFH and STEC infection treated with eculizumab in a 4-year-old girl. Galvez C; Krall P; Rojas A; Oh J; Cano F Pediatr Nephrol; 2023 Apr; 38(4):1195-1203. PubMed ID: 35969277 [TBL] [Abstract][Full Text] [Related]
13. Eculizumab in Shiga toxin-producing Escherichia coli hemolytic uremic syndrome: a systematic review. de Zwart PL; Mueller TF; Spartà G; Luyckx VA Pediatr Nephrol; 2024 May; 39(5):1369-1385. PubMed ID: 38057431 [TBL] [Abstract][Full Text] [Related]
14. Best supportive care and therapeutic plasma exchange with or without eculizumab in Shiga-toxin-producing E. coli O104:H4 induced haemolytic-uraemic syndrome: an analysis of the German STEC-HUS registry. Kielstein JT; Beutel G; Fleig S; Steinhoff J; Meyer TN; Hafer C; Kuhlmann U; Bramstedt J; Panzer U; Vischedyk M; Busch V; Ries W; Mitzner S; Mees S; Stracke S; Nürnberger J; Gerke P; Wiesner M; Sucke B; Abu-Tair M; Kribben A; Klause N; Schindler R; Merkel F; Schnatter S; Dorresteijn EM; Samuelsson O; Brunkhorst R; Nephrol Dial Transplant; 2012 Oct; 27(10):3807-15. PubMed ID: 23114903 [TBL] [Abstract][Full Text] [Related]
15. Hemolytic uremic syndrome: differential diagnosis with the onset of inflammatory bowel diseases. Bianchi L; Gaiani F; Vincenzi F; Kayali S; Di Mario F; Leandro G; De' Angelis GL; Ruberto C Acta Biomed; 2018 Dec; 89(9-S):153-157. PubMed ID: 30561409 [TBL] [Abstract][Full Text] [Related]
16. Outbreak of Shiga toxin-producing Escherichia-coli-associated hemolytic uremic syndrome in Istanbul in 2015: outcome and experience with eculizumab. Ağbaş A; Göknar N; Akıncı N; Yıldırım ZY; Taşdemir M; Benzer M; Gökçe İ; Candan C; Küçük N; Uzuner S; Özçelik G; Demirkol D; Sever L; Çalışkan S Pediatr Nephrol; 2018 Dec; 33(12):2371-2381. PubMed ID: 30159625 [TBL] [Abstract][Full Text] [Related]
18. Severely ill pediatric patients with Shiga toxin-associated hemolytic uremic syndrome (STEC-HUS) who suffered from multiple organ involvement in the early stage. Luna M; Kamariski M; Principi I; Bocanegra V; Vallés PG Pediatr Nephrol; 2021 Jun; 36(6):1499-1509. PubMed ID: 33205220 [TBL] [Abstract][Full Text] [Related]
19. Outbreak of hemolytic uremic syndrome with unusually severe clinical presentation caused by Shiga toxin-producing Escherichia coli O26:H11 in France. Minary K; Tanne C; Kwon T; Faudeux C; Clave S; Langevin L; Pietrement C; Enoch C; Parmentier C; Mariani-Kurkdjian P; Weill FX; Jones G; Djouadi N; Morin D; Fila M Arch Pediatr; 2022 Aug; 29(6):448-452. PubMed ID: 35662540 [TBL] [Abstract][Full Text] [Related]
20. Eculizumab Use in a Temporarily Dialysis-Dependent Patient With Shiga Toxin-Producing Weber B; Chan D; Hammer S J Pediatr Pharmacol Ther; 2022; 27(1):90-95. PubMed ID: 35002565 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]